Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$6.29
+5.4%
$6.63
$4.34
$12.38
$370.86M0.45152,179 shs403,768 shs
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$6.29
-0.9%
$7.55
$6.24
$18.62
$375.12M-0.08534,538 shs457,679 shs
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$7.30
+3.3%
$7.07
$2.32
$8.50
$382.43M2.82379,554 shs380,436 shs
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
$2.10
+8.5%
$2.09
$0.27
$3.25
$96.68M0.531.83 million shs1.97 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-3.40%-7.73%-11.16%-3.40%-40.71%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-2.76%-7.16%-17.10%-23.68%-64.62%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
+1.00%-2.75%+3.67%+9.95%+122.33%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
0.00%0.00%+4.75%+121.39%+212.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$6.29
+5.4%
$6.63
$4.34
$12.38
$370.86M0.45152,179 shs403,768 shs
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$6.29
-0.9%
$7.55
$6.24
$18.62
$375.12M-0.08534,538 shs457,679 shs
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$7.30
+3.3%
$7.07
$2.32
$8.50
$382.43M2.82379,554 shs380,436 shs
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
$2.10
+8.5%
$2.09
$0.27
$3.25
$96.68M0.531.83 million shs1.97 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-3.40%-7.73%-11.16%-3.40%-40.71%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-2.76%-7.16%-17.10%-23.68%-64.62%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
+1.00%-2.75%+3.67%+9.95%+122.33%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
0.00%0.00%+4.75%+121.39%+212.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
3.00
Buy$22.00249.76% Upside
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3.00
Buy$27.67339.85% Upside
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
3.00
Buy$9.6031.51% Upside
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
3.00
Buy$4.0090.93% Upside

Current Analyst Ratings Breakdown

Latest IPA, CGEM, AURA, and FULC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/12/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00
9/10/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$32.00
8/21/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$24.00
8/19/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
8/18/2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$35.00 ➝ $28.00
8/13/2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$22.00
7/30/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSector Perform$4.00 ➝ $5.00
7/29/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$4.00 ➝ $12.00
(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/A$3.04 per shareN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/A$10.14 per shareN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$80M4.94N/AN/A$4.51 per share1.62
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
$17.59M5.50N/AN/A$0.37 per share5.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$86.92M-$1.96N/AN/AN/AN/A-64.44%-54.24%11/11/2025 (Estimated)
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$167.38M-$3.23N/AN/AN/AN/A-36.56%-34.82%11/6/2025 (Estimated)
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%11/12/2025 (Estimated)
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-$21.69M-$0.68N/AN/AN/A-122.10%-40.62%-22.19%N/A

Latest IPA, CGEM, AURA, and FULC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.49-$0.47+$0.02-$0.47N/AN/A
8/7/2025Q2 2025
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.83-$1.07-$0.24-$1.07N/AN/A
7/29/2025Q2 2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.29-$0.28+$0.01-$0.28N/AN/A
7/29/2025Q4 2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-$0.02-$0.04-$0.02-$0.04$7.89 million$5.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/AN/A
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/AN/A
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/AN/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/A
12.39
12.39
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/A
9.83
9.83
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/A
24.42
24.42
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
0.49
2.08
1.85

Institutional Ownership

CompanyInstitutional Ownership
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
96.75%
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
86.31%
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
89.83%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
6.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5062.12 million58.21 millionNot Optionable
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3059.07 million55.49 millionOptionable
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
10054.09 million50.31 millionOptionable
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
8046.15 million43.00 millionNot Optionable

Recent News About These Companies

IPA Europe Rebrands as AVS Bio, Marking Next Phase of Growth

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aura Biosciences stock logo

Aura Biosciences NASDAQ:AURA

$6.29 +0.32 (+5.36%)
Closing price 04:00 PM Eastern
Extended Trading
$6.45 +0.16 (+2.54%)
As of 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Cullinan Therapeutics stock logo

Cullinan Therapeutics NASDAQ:CGEM

$6.29 -0.06 (-0.94%)
Closing price 04:00 PM Eastern
Extended Trading
$6.28 0.00 (-0.08%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics stock logo

Fulcrum Therapeutics NASDAQ:FULC

$7.30 +0.23 (+3.25%)
Closing price 04:00 PM Eastern
Extended Trading
$7.48 +0.18 (+2.45%)
As of 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

ImmunoPrecise Antibodies stock logo

ImmunoPrecise Antibodies NASDAQ:IPA

$2.10 +0.17 (+8.55%)
Closing price 09/3/2025
Extended Trading
$2.10 0.00 (0.00%)
As of 09/3/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.